Literature DB >> 18022866

Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.

Taina Sipponen1, Erkki Savilahti, Kaija-Leena Kolho, Hannu Nuutinen, Ulla Turunen, Martti Färkkilä.   

Abstract

BACKGROUND: Correlation of endoscopic Crohn's disease activity with fecal calprotectin and lactoferrin is insufficiently studied. We evaluated the clinical significance of these neutrofil-derived proteins in assessment of Crohn's disease activity by comparing them with endoscopic disease activity and with Crohn's disease activity index (CDAI) and serum CRP.
METHODS: A total of 77 CD patients underwent one or more ileocolonoscopies (n = 106) with scoring of Crohn's disease index of severity (CDEIS). Patients provided stool samples for calprotectin and lactoferrin measurements and blood samples for CRP. Clinical activity was based on the CDAI.
RESULTS: Both fecal calprotectin and lactoferrin correlated significantly with CDEIS (Spearman's r 0.729 and 0.773, P < 0.001). With a cutoff level of 200 microg/g for a raised fecal calprotectin concentration, sensitivity was 70%, specificity 92%, positive predictive value (PPV) 94%, and negative predictive value (NPV) 61% in predicting endoscopically active disease (CDEIS >/= 3). A fecal lactoferrin concentration of 10 microg/g as the cutoff value gave a sensitivity, specificity, PPV, and NPV of 66%, 92%, 94%, and 59%. Sensitivity of CDAI >/= 150 to detect endoscopically active disease was only 27%, specificity 94%, PPV 91%, and NPV 40%. A raised serum CRP (> 5 mg/l) gave a sensitivity, specificity, PPV, and NPV of 48%, 91%, 91%, and 48%.
CONCLUSIONS: For evaluation of Crohn's disease activity, based on endoscopic findings, more sensitive surrogate markers than is CDAI or CRP are fecal calprotectin and lactoferrin. These prove to be useful tools for estimation of disease activity in Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18022866     DOI: 10.1002/ibd.20312

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  130 in total

1.  Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India.

Authors:  Geir Larsson; Koticherry Thrivikrama Shenoy; Ramalingom Ramasubramanian; Lakshmikanthan Thayumanavan; Leena Kondarappassery Balakumaran; Gunnar A Bjune; Bjørn A Moum
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

Review 2.  Mucosal healing in inflammatory bowel disease: where do we stand?

Authors:  Christina Ha; Asher Kornbluth
Journal:  Curr Gastroenterol Rep       Date:  2010-12

Review 3.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin.

Authors:  Jesica C Makanyanga; Doug Pendsé; Nikolaos Dikaios; Stuart Bloom; Sara McCartney; Emma Helbren; Elaine Atkins; Terry Cuthbertson; Shonit Punwani; Alastair Forbes; Steve Halligan; Stuart A Taylor
Journal:  Eur Radiol       Date:  2013-09-12       Impact factor: 5.315

Review 5.  Advances in epidemiology and diagnosis of inflammatory bowel diseases.

Authors:  Sobia Ali; Cyrus P Tamboli
Journal:  Curr Gastroenterol Rep       Date:  2008-12

Review 6.  Clinical implications of mucosal healing for the management of IBD.

Authors:  Guillaume Pineton de Chambrun; Laurent Peyrin-Biroulet; Marc Lémann; Jean-Frédéric Colombel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-12-01       Impact factor: 46.802

Review 7.  Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors:  Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

Review 8.  Mucosal healing and deep remission: what does it mean?

Authors:  Gerhard Rogler; Stephan Vavricka; Alain Schoepfer; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 9.  Postoperative Crohn's disease recurrence: a practical approach.

Authors:  Pilar Nos; Eugeni Domenech
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

10.  Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire.

Authors:  Cesare Ruffolo; Marco Scarpa; Diego Faggian; Daniela Basso; Renata D'Incà; Mario Plebani; Giacomo C Sturniolo; Nicolò Bassi; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2009-11-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.